SCHEMBL6785990

SCHEMBL6785990

C/C(=C/C(=O)Nc1ccccc1C(=O)O)c1ccc(Br)c(Br)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.72
DHODH Q02127 3/20 0.50
TRPM8 Q7Z2W7 2/20 0.50
TRPA1 O75762 1/20 0.47
LTB4R Q15722 1/20 0.46
DEGS1 O15121 1/20 0.45
AKR1B10 O60218 1/20 0.45
AKR1B1 P15121 1/20 0.45
AKR1C4 P17516 1/20 0.45
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
AKR1C1 Q04828 1/20 0.45
MEN1 O00255 1/20 0.45
PKM P14618 1/20 0.45
KMT2A Q03164 1/20 0.45
PTGES O14684 1/20 0.44
ALOX5 P09917 1/20 0.44
LMNA P02545 1/20 0.44
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025243 0.89 TERT (0.67) TERTDHODHTRPM8TRPA1LTB4R
SCHEMBL6785189 0.89 TERT (0.67) TERTDHODHTRPM8TRPA1LTB4R
SCHEMBL6786210 0.84 TERT (0.61) TERTDHODHTRPM8TRPA1LTB4R
SCHEMBL4022937 0.84 TERT (1.00) TERTDHODHLTB4RDEGS1AKR1B10
SCHEMBL29966843 0.84 TERT (1.00) TERTDHODHLTB4RDEGS1AKR1B10
SCHEMBL29362821 0.84 TERT (1.00) TERTDHODHLTB4RDEGS1AKR1B10
SCHEMBL16964998 0.84 TERT (1.00) TERTDHODHLTB4RDEGS1AKR1B10
SCHEMBL111092 0.84 TERT (0.73) TERTDHODHTRPM8LTB4RDEGS1
SCHEMBL30760782 0.84 TERT (1.00) TERTDHODHLTB4RDEGS1AKR1B10
SCHEMBL29355750 0.84 TERT (1.00) TERTDHODHLTB4RDEGS1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US claimed
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885DHODH 1011/4885TRPM8 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.